We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vertex’s Kalydeco Gets New FDA Approval for Cystic Fibrosis
Vertex’s Kalydeco Gets New FDA Approval for Cystic Fibrosis
Vertex Pharmaceuticals’ cystic fibrosis drug Kalydeco has won FDA approval for an additional indication to treat patients six years and older with at least one copy of the R117H gene mutation.